At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ODD ODDITY Tech Ltd.
Post-Mkt 04-22 17:46:55 EDT
15.74
+0.26
+1.68%
盘后15.74
+0.000.00%
16:33 EDT
High16.00Low15.54Vol1.09M
Open15.56D1 Closing15.48Amplitude2.97%
Mkt Cap891.78MTradable Cap616.48MTotal Shares56.66M
T/O17.08MT/O Rate2.77%Tradable Shares39.17M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies
GlobeNewswire  ·  04-21 21:47
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies
Medicus Pharma submits ODD application to U.S. FDA for SkinJect
TIPRANKS  ·  04-17
Medicus Pharma submits ODD application to U.S. FDA for SkinJect
ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep
The West Australian  ·  04-17
ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep
Oddity Tech faces securities class action over alleged misleading ad efficiency disclosures
Reuters  ·  04-16
Oddity Tech faces securities class action over alleged misleading ad efficiency disclosures
A Look At Oddity Tech (ODD) Valuation As Securities Class Action Raises Questions On Customer Acquisition Costs
Simply Wall St.  ·  04-11
A Look At Oddity Tech (ODD) Valuation As Securities Class Action Raises Questions On Customer Acquisition Costs
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire  ·  04-09
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results
GlobeNewswire  ·  04-09
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
GlobeNewswire  ·  04-08
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
Kodiak AI Expands Autonomous Trucking Beyond the Sunbelt with Demonstrations in Ohio and Indiana
GlobeNewswire  ·  04-08
Kodiak AI Expands Autonomous Trucking Beyond the Sunbelt with Demonstrations in Ohio and Indiana
Oddity Tech (ODD) Faces Investor Lawsuit Over Alleged Ad Algorithm Disclosures
TIPRANKS  ·  04-08
Oddity Tech (ODD) Faces Investor Lawsuit Over Alleged Ad Algorithm Disclosures
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
GlobeNewswire  ·  03-30
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Press Release: Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Dow Jones  ·  03-30
Press Release: Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
ODDITY Tech Is Maintained at Neutral by Goldman Sachs
Dow Jones  ·  03-28
ODDITY Tech Is Maintained at Neutral by Goldman Sachs
Oddity Tech Faces Securities Lawsuit After Stock Drops Nearly 50% on Advertising Disruption Disclosure
TIPRANKS  ·  03-26
Oddity Tech Faces Securities Lawsuit After Stock Drops Nearly 50% on Advertising Disruption Disclosure
Oddity Tech director Michael Farello files initial beneficial ownership statement
Reuters  ·  03-25
Oddity Tech director Michael Farello files initial beneficial ownership statement
Key Corporate Announcements Summary for March 24 Evening
Deep News  ·  03-24
Key Corporate Announcements Summary for March 24 Evening
Belief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients
prnewswire  ·  03-23
Belief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients
Oddity Tech Director Lilach Payorski Files Initial Beneficial Ownership Statement
Reuters  ·  03-21
Oddity Tech Director Lilach Payorski Files Initial Beneficial Ownership Statement
Oddity Tech Ltd. director Cheresniya Ohad files initial beneficial ownership statement
Reuters  ·  03-21
Oddity Tech Ltd. director Cheresniya Ohad files initial beneficial ownership statement
Oddity Tech Ltd. CTO Niv Price Files Initial Beneficial Ownership Statement
Reuters  ·  03-21
Oddity Tech Ltd. CTO Niv Price Files Initial Beneficial Ownership Statement

Introduction

Company Name.
ODDITY Tech Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.
Issue price:
--